|
Company |
Industry |
Transaction |
NGP Role |
Business Description |
 |
Nuclear Pharmaceuticals,
Medically important radioisotopes |
License of Technology, supply agreements,
presentations to private investors and equity players |
Founder, Preparation of
business plan, securing necessary financing, negotiating all necessary
license agreements, market research, infrastructure, execution |
NGP and its principals George P. Messina
and Glenn H. Isensee are the founders of the new entity
NorthStar Nuclear Medicine, LLC.
Worldwide license rights for the patented technologies have been granted to
NGP and include separation chemistries and a revolutionary laboratory
device. Initial fund raising will be done by
NGP and staffing of the company with creative and respected
talent will be completed. |
|
NorthStar Life
Sciences |
Biotechnology,
Molecular Biology |
Completing research
and business viability investigations |
Founder,
Preparation of business plan, securing necessary financing, negotiate
technology arrangements, market research, infrastructure, execution |
NGP and its principals George P. Messina
and Glenn H. Isensee will be the founders of the new entity
NorthStar Life Sciences. The
license rights to patented technologies include molecular identification and
detection. Initial fund raising will be done by
NGP and staffing of the company with creative and respected
talent will be completed. NGP
will be responsible for executing the overall development and operational
strategies. |
|
Advanced Engineered Systems
Inc. |
Custom Engineering
and Manufacturing Equipment |
Restructured debt
and provided financial support |
Financial advisory
support, development of a strategic business plan, implementation of
best business practices |
Provided the CEO
with support for the restructuring of the company's debt while strengthening the corporate balance
sheet and managing to improve profitability. Provided a Line
of Credit to meet the growth planned for 2004. The company continues
to exceed historical precedence and is
exceeding proforma revenues as a direct result of the
value-building expertise provided by NGP
in restructuring, financials, marketing and disciplined growth.
|
|
Medical
Device Company |
Medical Diagnostic
Devices |
Raised $8M in
equity, $3M in mezzanine and $10M senior debt |
Founder, Exclusive
financial advisor, strategic planning, operations, staffing, execution |
Founded by the
principals of NGP, the company has
successfully obtained commitments for financial
funding, developed its business strategy, identified acquisition targets,
negotiating their acquisition, identified and negotiated access to additional
new innovative technologies, managing all integration and operational
efforts. |
|
A Technology Company |
Specialty
Manufacturing |
Strategic plan,
execution, introductions to new markets |
Financial
and Corporate Advisor |
Guidance and support for the restructuring of the company's debt, improving
its corporate balance sheet and turning the company around to profitability,
solving all issues with judgments and associated lawsuits,
changed the corporate culture to one of enthusiasm and revived entrepreneurial spirit. |
|
SORBA Medical Systems |
Medical Diagnostic
Devices |
Licensed
Technology |
Exclusive
financial advisor |
Company was in a
distressed sell situation. NGP
re-negotiated and managed a sale of its technology in excess of $2.0M ( a 4X
improvement in previous offers). Purchased by a public company for
cash and stock. During NGP's
involvement, additional capital was raised to keep the company
operating and it provided leadership and guidance in negotiations and
solving a difficult lawsuit with investors. |
|
Burdick, Inc |
Medical Diagnostic
Devices |
Acquisition |
Acting CEO under
Siemens |
Acquired Burdick
Inc. from Siemens Medical Systems for $13.0M at a time when revenues were
$28.0M |
| Burdick, Inc |
$7.5M in equity,
$13.5M in senior debt |
MBO Acquisition
and funding |
CEO, negotiated
and secured a crucial technology license with the University of Glasgow in
Scotland, found and negotiated with investors |
Secured financial
funding for working capital and acquisition, negotiated and orchestrated a
co-exclusive technology license with Siemens for the University of Glasgow's
ECG interpretive algorithm. |
| Burdick, Inc |
$2.5M in debt |
Funding an
Acquisition |
CEO, contacted and
negotiated acquisition of a publicly held company |
Financed the
purchase of a publicly held company - Diagnostic Measurements, Inc. of
Syracuse, NY. Strategic solution to Burdick's product portfolio gap |
| Burdick, Inc |
$1.0M in debt |
Funding an
Acquisition |
CEO, contacted and
negotiated acquisition of a privately held company |
Financed the
purchase of a publicly held company - Tamarack, Inc., a privately held
company in Denver, CO. Strategic solution to Burdick's product
portfolio gap |
| Burdick, Inc |
$0.8M in debt |
Creation of a
China Joint Venture |
CEO, contacted and
negotiated all terms with partner and Chinese government |
Funded and secured
all licensing to create a joint venture, Shanghai Burdick Instrumentation
Company, in Shanghai, PRC to produce and distribute products in the Asian
marketplace. |
|
Burdick, Inc** |
$52M |
Sale to
Spacelabs Medical Inc.,
Redmond, WA. (currently Spacelabs Healthcare) |
CEO, contacted and
managed the negotiations and closing of the deal |
Found a strategic
buyer for Burdick in less than four (4) years after MBO. Revenues at
the point of acquisition were $52.0M. Negotiated the terms of
the deal and participated in closing. Total price with all debt
(including OPEB) was $52M.
**Company currently operates under the corporate structure of Cardiac
Science CSCX:NASDAQ |
|
Start-up of
Mignone Communications, Inc. |
Printing
|
$700K in equity
and $7.2M in senior debt and operating lease agreements |
Formation of the
start-up, structuring the new company, and procuring the required funding. |
Company founded by
a medical doctor and a supervisor from a closely held printing company.
Negotiated the acquisition of a facility, all credit facilities and
covenants, and the lease of a $3.5M web-press. Resolved a
long-standing issue concerning a buy/sell agreement between shareholders.
Orchestrated the exit from the deal by timing the sale of the facility, with
the paying down of the debt and the final acquisition of a major
shareholder's stock. Provided the CEO and CFO with in-depth education
on how to run and finance a business. ROI for the existing
shareholders exceeded three times the initial investment. |
|
Medical Distribution Solutions,
Inc. |
Medical
Publications |
Acquisition |
Exclusive financial advisor and
follow-up services |
Acquired Neoforma,
Inc.'s US LifeLine.com business. Negotiated the price, managed and
supported all due diligence activities, managed the negotiation of the
Asset Purchase Agreement, took part in integration of the two companies
after closing and restructured the Holding Company for tax purposes as well
as financing sources |
| Medical
Distribution Solutions, Inc. |
Medical
Publications |
$0.8M in equity
and services contracts and $1.25M in debt. |
Exclusive
financial advisor, securing financing |
Purchase price of
the deal was $1.25M |
|
Quality Assured Services |
Home Testing
Services |
Preparation of
presentations to potential investors |
Financial advisor |
Presentations to
major venture capitalist investors. |
|
Chemical Company |
Chemical Refinery |
$16M in equity and
$15M in Mezzanine |
Exclusive
financial advisor, secured potential financing |
Raised the
necessary funds indicated in two weeks. The term sheet provided was
100% acceptable to the CEO, but the selling party decided not to sell its
share (~38% of the company). By
request the CEO is available by reference only, please contact
NGP for further
detail. |
